CJC-1295 without DAC

What CJC-1295 without DAC does

“CJC-1295 no DAC” usually means modified GRF 1-29, a different molecule from trial-tested CJC-1295 with DAC. People often pair it with ipamorelin for sleep, recovery or body composition. No published human dosing study was found for this exact compound. Human half-life, effective dose and long-term safety remain unknown. It has no FDA approval.

• People report better sleep or recovery, while others report no benefit. (Reported by users)
• People report using it for muscle and body composition goals; no controlled human study has tested this. (Reported by users)
• People report pairing it with ipamorelin for exercise recovery; the benefit and safety of the pair are untested. (Reported by users)

Uses in the sources

• Users report body-composition and muscle goals. No controlled human benefit study for modified GRF 1-29 was found. (Reported by users) (source)
• Reported with ipamorelin for exercise recovery; benefit and combination safety are untested. (Reported by users) (source)
• Sleep reports conflict: some describe improvement, others disturbed sleep and vivid dreams. (Reported by users) (source)

CJC-1295 without DAC dosage

Typical reported dose: 100–200 mcg at bedtime, often with ipamorelin

• Nightly no-DAC pairing: 100–200 mcg no DAC plus 100–200 mcg ipamorelin once nightly, under the skin. Reported by users, common report. Studied in: Adult self-users reporting online; identity, dose and outcomes are unverified. (source)
• Morning and bedtime report: 100 mcg no DAC in the morning; 200 mcg at bedtime twice daily, under the skin. Reported by users, occasional report. Studied in: Adult self-users reporting online; identity, dose and outcomes are unverified. (source)
• 300 mcg, five nights weekly: 300 mcg no DAC plus 300 mcg ipamorelin at bedtime nightly, five days on and two days off, under the skin. Reported by users, occasional report. Studied in: Adult self-users reporting online; identity, dose and outcomes are unverified. (source)
• Forum cycle described in a review: 100–200 mcg per injection, once or twice daily once or twice daily, under the skin. Reported by users, common report. Studied in: Adult self-users reporting online; identity, dose and outcomes are unverified. (source)
• Single high-dose outlier: 2 mg daily, reported by one commenter once daily, under the skin. Reported by users, rare report. Studied in: Adult self-users reporting online; identity, dose and outcomes are unverified. (source)

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

How to mix CJC-1295 without DAC

Comes as: Freeze-dried powder vial., Reported blend containing 5 mg modified GRF 1-29 plus 5 mg ipamorelin..

Mixed with: Users report bacteriostatic water; no approved diluent or mixing schedule exists..

Common vial sizes: 2, 5 mg. Common water amounts: 2, 2.5, 3 mL.

• A 5 mg + 5 mg blend has 10 mg total peptide, but only 5 mg of each ingredient. Calculate each ingredient separately.
• Reported 2–3 mL water volumes describe practice; they do not establish compatibility or sterility.
• Haze or particles were reported after mixing; do not inject a visibly abnormal preparation.
• Bacteriostatic water does not sterilize contaminated powder. A clear vial can still contain microbes or endotoxin.
• Do not borrow a 28-day expiry or storage instructions from another peptide or its diluent.

Before mixing: FDA reviews describe frozen research powder, often below −20°C. No validated patient-product shelf life was found.

After mixing: Users report refrigeration. No validated mixed-vial stability or beyond-use date was found for these preparations.

CJC-1295 without DAC side effects and risks

Reported side effects

• Flushing and injection reactions: Reported in no DAC/ipamorelin threads; no denominator or verified product identity., moderate (source)
• Disturbed sleep or vivid dreams: Conflicting user reports with ipamorelin; no clinical event rate., mild (source)
• Racing heart: One thread includes a heart rate report up to 130 beats/min with the combination; cause is unverified., serious. Persistent racing heart, chest pain or fainting needs urgent care. (source)
• Blood sugar changes, swelling or joint pain: Related tesamorelin can cause these effects. Modified GRF 1 29 risks and rates are unknown., moderate (source)
• Allergic reaction or contaminated-injection infection: Unapproved injectable product risk; no modified GRF specific incidence estimate., serious (source)

Stop and get help if

• Trouble breathing, throat or face swelling, widespread hives, or collapse: Stop using it and call emergency services now.
• Chest pain, fainting, severe breathlessness, or a sustained racing heart: Stop exposure and seek emergency care now.
• Severe headache with vision change, vomiting, or new weakness: Get emergency care now; do not assume this is normal flushing.
• Rapid swelling or weight gain with shortness of breath: Seek urgent care now for possible fluid overload or heart problems.
• Hot spreading injection-site redness, severe pain, pus, or fever: Stop injections and get urgent same-day care; fever or rapidly worsening illness needs emergency care.
• Confusion, vomiting, marked thirst or urination, or low sugar that does not improve: Check blood sugar if available and seek urgent care; severe confusion or unconsciousness needs emergency services.

Who should avoid it

• pregnant: CJC pregnancy safety is unknown. Stop use during pregnancy.
• breastfeeding: Milk transfer and infant effects are unknown; avoid exposing a nursing infant.
• tryingToConceive: Fertility and early-pregnancy effects are unknown. This is a precautionary screen.
• under18: No child safety study was found. Growth hormone stimulation can affect growth.
• activeCancer: Growth hormone can support cell growth. Avoid no-DAC CJC with active cancer, following related-drug precautions.
• cancerHistory: A prior cancer needs individual review; long-term recurrence risk with CJC is unknown.
• other: Excess growth hormone makes this unsuitable; pituitary disease needs specialist review.
• other: A serious allergy to this peptide or its vial ingredients means avoiding further use.
• diabetes: Growth hormone can raise blood sugar. Diabetes was excluded from the HIV study; no-DAC safety data are lacking.
• diabeticRetinopathy: Related tesamorelin guidance warns about worsening diabetic eye disease; no-DAC CJC risk is unknown.
• heartCondition: No-DAC cardiac effects are unmeasured; fast heart rate is reported in users taking it with ipamorelin.
• uncontrolledBloodPressure: Blood-pressure instability and GH-related fluid retention warrant review before further exposure.
• sleepApnea: Sleep apnea raises baseline cardiometabolic risk; new snoring or breathing pauses need assessment.
• kidneyDisease: No kidney dosing study was found. Kidney disease can also cause swelling and change hormone tests.
• liverDisease: No liver dosing study was found; liver disease can distort IGF-1 blood tests.
• surgeryPlanned: Tell the anesthesia team about peptide and other hormone use; no perioperative CJC safety study was found.
• testedAthlete: WADA prohibits GHRH analogues at all times, including CJC-1295.

Interactions

• Insulin: Related tesamorelin can raise blood sugar. No-DAC CJC effects on insulin needs are unknown; review readings with your clinician when use starts or stops.
• Sulfonylureas: No-DAC CJC interactions are unknown. These medicines can cause severe low blood sugar; review readings with your clinician when use changes.
• Other GH, GHRH or ghrelin-pathway drugs: Effects may add, raising IGF-1 or glucose and fluid-retention concerns. No CJC/ipamorelin combination trial was found.
• Glucocorticoid replacement: Tesamorelin's label warns growth hormone can lower cortisol and change steroid replacement needs. No-DAC CJC effects are unknown.
• Medicines affected by liver CYP enzymes: Tesamorelin's label warns growth hormone may change drug breakdown. No-DAC CJC interactions remain unknown.
• Anticoagulants: Blood thinners increase bleeding and bruising from needle punctures. A direct CJC drug interaction has not been demonstrated.

Product quality risks

• DAC and no-DAC names are confused. FDA considers them different active moieties with different safety and exposure profiles.
• FDA found missing impurity, aggregate and endotoxin data in reviewed certificates. A high purity percentage alone cannot show injection safety.
• A 2010 seized sample contained a 29-amino-acid peptide consistent with the short form sold as CJC-1295; it was not proof of DAC identity.
• A 2019 seizure study identified glycine-added modified GRF and other secretagogues. Seized material is not a representative market survey.
• Regulators warn unapproved peptide vials may have too much, too little or no stated ingredient, particles, microbes or endotoxin.

What to expect

No human dosing study found for modified GRF 1-29; DAC trials tested another molecule. Lab tests and forums do not prove safety or benefits.

Key studies

• Henninge 2010: seized peptide: A marketed name did not establish that a preparation contained the DAC molecule used in human trials. (source)
• Gajda 2019: altered GRF in seizures: Seized material included altered peptide sequences; a familiar name alone cannot establish identity. (source)

CJC-1295 without DAC FAQ

• Is CJC-1295 without DAC FDA-approved? No approved CJC product or dose label. Withdrawal from Category 2 did not establish approval or a Category 1 compounding pathway.
• How do people take it? Under the skin, once nightly. Source: reported by users, not an established dose.
• What's the difference between CJC-1295 without DAC and Ipamorelin? CJC-1295 without DAC: a peptide intended to trigger growth hormone release, with no human dosing study found. Ipamorelin: an experimental peptide that triggers growth hormone release. Why people pair them: users combine a GHRH signal with a ghrelin signal hoping for greater GH release. No human trial tested this exact pairing.
• Can I take it with Ipamorelin? Users combine a GHRH signal with a ghrelin signal hoping for greater GH release. No human trial tested this exact pairing. No validated dose ratio or safety estimate; endocrine and glucose effects may add. Source: reported by users. Ask a doctor before combining anything.
• Is it banned in sport? Yes. It is banned in and out of competition (WADA 2026). Growth hormone releasing factors, including GHRH analogues. Covers DAC and modified GRF 1-29.
• How long does a mixed vial last? Users report refrigeration. No validated mixed-vial stability or beyond-use date was found for these preparations.